COVID-19 Funding Snapshot for Pharma Developers/Manufacturers Views as of August 7, 2020 Presentations August 21, 2020 Lain Anderson Cassie Guo Adam Nover
Contributing authors: Tony Stripling, Associate Consultant Sean Saunders, Life Sciences Speciaist Jennifer Henry, Associate Consultant Patrick Marquet, Associate Related Practice Life Sciences & Pharma The COVID-19 pharmaceutical funding landscape is evolving at a rapid pace, yet several initial insights have emerged 01262022160100
Executive Insights Contract/Pharma Services Key Trends for CDMOs Partnering With Cell Therapy Developers July 11, 2024
Podcast Life Sciences & Pharma A New Generation of Drug Therapies Requires New Business Strategies July 10, 2024
Published Articles Mergers & Acquisitions The Integration Triangle - Understanding the Critical Linkages That Make (Or Break) Value… November 16, 2023
Executive Insights Life Sciences & Pharma Initial Drugs Selected for Medicare Price Negotiation: Emerging Perspectives September 1, 2023
Executive Insights Life Sciences & Pharma Navigating the Shifting Landscape in Life Sciences: Trends and Implications July 31, 2023